Svensson E, Eisensmith R C, Dworniczak B, von Döbeln U, Hagenfeldt L, Horst J, Woo S L
Howard Hughes Medical Institute, Department of Cell Biology, Houston, Texas.
Hum Mutat. 1992;1(2):129-37. doi: 10.1002/humu.1380010208.
The genetic defects responsible for most phenylketonuria (PKU) and hyperphenylalaninemia (HPA) cases are located in the phenylalanine hydroxylase (PAH) gene. Approximately 50-60 mutations have been reported in Caucasians and are reflected in a wide range of clinical severities. Most mutations are linked to specific haplotypes, as defined by eight polymorphic restriction sites in the PAH gene. We hypothesized that there is at least one mild mutation linked to haplotype 12 in the Swedish PKU/HPA population, since 7 of 8 patients carrying haplotype 12 had mild HPA. Sequence analysis revealed a C-to-G transversion at the second base of codon 322, resulting in a substitution of glycine for alanine, in four mutant haplotype 12 genes, and a G-to-A transition at the second base of codon 408, resulting in a substitution of glutamine for arginine, in another three mutant haplotype 12 genes. These mutations segregated with mutant haplotype 12 alleles in nuclear families but were not present on normal or other mutant alleles. Both mutations were tested in a eukaryotic expression system in which enzyme activities of different mutant PAH enzymes reflect the relative severities of the mutations, although these in vitro activities cannot be translated directly into in vivo hepatic activities. The A322G mutant PAH had about 75% and the R408Q mutant PAH about 55% of the wild-type PAH enzyme activity. These in vitro activities are the highest reported for mutant PAH enzymes produced in the same expression system.(ABSTRACT TRUNCATED AT 250 WORDS)
导致大多数苯丙酮尿症(PKU)和高苯丙氨酸血症(HPA)病例的基因缺陷位于苯丙氨酸羟化酶(PAH)基因中。在白种人中已报道了约50 - 60种突变,这些突变反映在广泛的临床严重程度范围内。大多数突变与特定单倍型相关,这些单倍型由PAH基因中的八个多态性限制性位点定义。我们推测在瑞典PKU/HPA人群中至少有一个与单倍型12相关的轻度突变,因为携带单倍型12的8名患者中有7名患有轻度HPA。序列分析显示,在四个突变的单倍型12基因中,密码子322的第二个碱基发生了C到G的颠换,导致丙氨酸被甘氨酸取代;在另外三个突变的单倍型12基因中,密码子408的第二个碱基发生了G到A的转换,导致精氨酸被谷氨酰胺取代。这些突变在核心家庭中与突变的单倍型12等位基因分离,但在正常或其他突变等位基因上不存在。这两种突变都在真核表达系统中进行了测试,在该系统中不同突变PAH酶的酶活性反映了突变的相对严重程度,尽管这些体外活性不能直接转化为体内肝脏活性。A322G突变的PAH具有约75%的野生型PAH酶活性,R408Q突变的PAH具有约55%的野生型PAH酶活性。这些体外活性是在同一表达系统中产生的突变PAH酶所报道的最高活性。(摘要截断于250字)